Authors: Villalona-Calero, MA Eder, JP Toppmeyer, DL Allen, LF Fram, R Velagapudi, R Myers, M Amato, A Kagen-Hallet, K Razvillas, B Kufe, DW Von Hoff, DD Rowinsky, EK

Citation: Ma. Villalona-calero et al., Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies, J CL ONCOL, 19(3), 2001, pp. 857-869

Authors: Gallagher, J Fisher, C Sherman, B Munger, M Meyers, B Ellison, T Fischkoff, S Barchuk, WT Teoh, L Velagapudi, R

Citation: J. Gallagher et al., A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome, INTEN CAR M, 27(7), 2001, pp. 1169-1178

Authors: Supko, JG Lynch, TJ Clark, JW Fram, R Allen, LF Velagapudi, R Kufe, DW Eder, JP

Citation: Jg. Supko et al., A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion, CANC CHEMOT, 46(4), 2000, pp. 319-328

Authors: Mross, K Berdel, WE Fiebig, HH Velagapudi, R von Broen, IM Unger, C

Citation: K. Mross et al., Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer, ANN ONCOL, 9(12), 1998, pp. 1323-1330